Put Options

7 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.47 - $11.18 $37,350 - $55,900
5,000 New
5,000 $39,000
Q1 2024

May 15, 2024

BUY
$7.3 - $9.46 $6,570 - $8,514
900 Added 47.37%
2,800 $23,000
Q4 2023

Feb 14, 2024

SELL
$7.85 - $11.18 $24,335 - $34,658
-3,100 Reduced 62.0%
1,900 $16,000
Q3 2023

Nov 14, 2023

SELL
$7.91 - $13.27 $26,103 - $43,791
-3,300 Reduced 39.76%
5,000 $51,000
Q2 2023

Aug 14, 2023

BUY
$9.27 - $14.88 $63,036 - $101,184
6,800 Added 453.33%
8,300 $107,000
Q1 2023

May 15, 2023

SELL
$8.85 - $13.27 $49,560 - $74,312
-5,600 Reduced 78.87%
1,500 $13,000
Q4 2022

Feb 14, 2023

BUY
$3.18 - $10.91 $22,578 - $77,461
7,100 New
7,100 $77,000

Others Institutions Holding PROF

About Profound Medical Corp.


  • Ticker PROF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 20,851,300
  • Market Cap $167M
  • Description
  • Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for...
More about PROF
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.